Business Wire

Earnix Survey Reveals Majority of Insurers Plan to Implement AI Predictive Models Within Two Years

4.11.2024 18:10:00 EET | Business Wire | Press release

Share

Earnix, the leading AI, real-time platform for intelligent decisioning SaaS solutions for the insurance and financial services industries, today announced its third annual survey on the state of the insurance market, the 2024 Industry Trends Report. The survey of over 400 global insurance executives uncovers key findings, trends, implications for what’s next in insurance, and sheds light on the role technology can play in shaping a better future.

Key findings from the 2024 survey include:

  • More than two-thirds (70%) of respondents expect to deploy AI models that make predictions based on real-time data in the next two years
  • More than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year
  • 58% of respondents take more than 5 months to implement a rule change and 21% take longer than 7 months
  • Insurers still need to move beyond legacy systems and fully modernize their operations, yet 49% admit they are behind schedule

“This year’s survey reveals the rapid use of AI, a 5–7-month average deployment of rule changes, as well as struggles with modernization,” said Robin Gilthorpe, CEO of Earnix. “Macroeconomic conditions such as inflation, climate change, cybersecurity risk, and uncertain economic conditions will also continue challenging insurers. Earnix is proud to be at the forefront of innovation in the insurance industry, and we look forward to working with insurers to help drive the technological growth the industry is experiencing to meet the modern needs of the market."

Among the key findings from the study, are that more than two-thirds (70%) of insurers are prioritizing the deployment of AI models that make predictions based on real-time data in the next two years, while less than one-third (29%) presently have them in place. While AI is not new to insurance, the entire industry is clearly increasing its adoption. Insurers reported that they expect the impact of AI to nearly double from last year to the current year, and then more than triple in the year ahead.

Regulatory compliance is another area of focus and insurers are now investing more time on it than in years past. More than two-thirds (70%) of respondents reported they will spend more time on regulatory compliance next year compared to this year, continuing a two-year trend. The reason for the time increase may be regulatory fines, as more than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year. As regulators catch up with technological advancements, new guidelines are likely to emerge, requiring insurers to continually update their frameworks. While failure to comply, will continue to become more severe.

“In today’s constantly changing landscape, it is critical for organizations to leverage AI models that provide real-time analytical data, enabling them to increase collaboration and innovation, drive product and business growth, and gain and retain market share,” said Aaron Wright, Director of Strategy at Earnix. “After years of talking about the implementation of this technology, we are finally seeing plans being put into action in this year's survey.”

About the Report

The survey, conducted by Earnix and Market Strategy Group, LLC in 2024 included 431 global insurance executives from the United States, Canada, Europe, and Australasia. Of those surveyed, 381 were from carriers with less than 20,000 employees and 50 executives from companies with more than 20,000 employees. The participants represented a range of roles and departments, including actuarial/pricing, analytics, product, underwriting, C-Suite, and IT/Technical roles.

Click here to download a full copy of the report.

About Earnix

Earnix is the premier provider of mission-critical, cloud-based intelligent solutions across pricing, underwriting, rating, and product personalization. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel.

Contact Earnix via LinkedIn, X, and Facebook. Read the Earnix blog.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104507752/en/

Contacts

Krystina Puleo
Global Director of External Communications
press@earnix.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye